Background:
Ang-(1-7) (H - Asp - Arg - Val - Tyr - Ile - His - Pro - OH) is an endogenous peptide fragment that can be produced from Ang I or Ang II via endo- or carboxy-peptidases respectively[1].
As described for Ang II, Ang-(1-7) also has a broad range of effects in different organs and tissues and goes beyond its initially described cardiovascular and renal actions. Those effects are mediated by Mas and can counter-regulate most of the deleterious effects of Ang II. The interaction Ang-(1-7)/Mas regulates different signaling pathways, such as PI3K (phosphoinositide 3-kinase)/AKT and ERK (extracellular signal-regulated kinase) pathways and involves downstream effectors such as NO, FOXO1 (forkhead box O1) and COX-2 (cyclo-oxygenase-2). Through these mechanisms, Ang-(1-7) is able to improve pathological conditions including fibrosis and inflammation in organs such as lungs, liver and kidney. [2]
In addition, this heptapeptide has positive effects on metabolism, increasing the glucose uptake and lipolysis while decreasing insulin resistance and dyslipidemia. Ang-(1-7) is also able to improve cerebroprotection against ischemic stroke, besides its effects on learning and memory. The reproductive system can also be affected by Ang-(1-7) treatment, with enhanced ovulation, spermatogenesis and sexual steroids synthesis. Finally, Ang-(1-7) is considered a potential anti-cancer treatment since it is able to inhibit cell proliferation and angiogenesis.[2]
参考文献:
1. Santos et al (2000) Angiotensin-(1-7): an update. Regul.Pept. 91 45.
2. Danielle G. P., Thiago V., Robson A. S. Angiotensin-(1-7): beyond the cardio-renal actions. Clinical Science (2013) 124, (443–456)
动态评分
0.0